DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel treatments for neurological and kidney diseases, today announced that it will be presenting at the H.C. Wainwright BioConnect 2021 Conference, being held virtually between January 11-14, 2021.
MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Inc. Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel treatments for neurological and kidney diseases, today announced that it will be presenting at the H.C. Wainwright BioConnect 2021 Conference, being held virtually between January 11-14, 2021.
The recorded presentation will be available on the Investors section of the Company’s website at https://ir.diamedica.com/events-and-presentations beginning Monday, January 11th.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing novel treatments for chronic kidney diseases and neurological disorders. DiaMedica’s shares are listed on The Nasdaq Capital Market under the trading symbol “DMAC.”
For more information, please visit www.diamedica.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005244/en/
Source: DiaMedica Therapeutics Inc.
View this news release online at:
http://www.businesswire.com/news/home/20210111005244/en
